|
1
|
Poorolajal J, Mahmoodi M, Majdzadeh R,
Nasseri-Moghaddam S, Haghdoost A and Fotouhi A: Long-term
protection provided by hepatitis B vaccine and need for booster
dose: a meta-analysis. Vaccine. 28:623–631. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shen T, Yan XM, Zou YL, Gao JM and Dong H:
Virologic characteristics of hepatitis B virus in patients infected
via maternal-fetal transmission. World J Gastroenterol.
14:5674–5682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kubba AK, Taylor P, Graneek B and Strobel
S: Non-responders to hepatitis B vaccination: a review. Commun Dis
Public Health. 6:106–112. 2003.PubMed/NCBI
|
|
4
|
Jin L, Wang G, Zhao X, et al:
Characterization and immune effect of the hepatitis B-BCG combined
vaccine for using a needle innoculation. Vaccine. 28:6041–6051.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanif SN, Al-Attiyah R and Mustafa AS: DNA
vaccine constructs expressing Mycobacterium tuberculosis-specific
genes induce immune responses. Scand J Immunol. 72:408–415. 2010.
View Article : Google Scholar
|
|
6
|
Qing Y, Chen M, Zhao J, et al:
Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to
the HBV-S gene and examination of its immune effects in normal and
HBV-transgenic mice. Vaccine. 28:4301–4307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park JH, Cho EW, Lee YJ, Shin SY and Kim
KL: Determination of the protective effects of neutralizing
anti-hepatitis B virus (HBV) immunoglobulins by epitope mapping
with recombinant HBV surface-antigen proteins. Microbiol Immunol.
44:703–710. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lian M, Zhou X, Chen B, Li C, Gu X, Luo M
and Zheng X: Identification of the critical regions in hepatitis B
virus preS required for its stability. J Pept Sci. 14:307–312.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Petersen J, Dandri M, Mier W, et al:
Prevention of hepatitis B virus infection in vivo by entry
inhibitors derived from the large envelope protein. Nat Biotechnol.
26:335–341. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park JH, Lee MK, Kim HS, Kim KL and Cho
EW: Targeted destruction of the polymerized human serum albumin
binding site within the preS2 region of the HBV surface antigen
while retaining full immunogenicity for this epitope. J Viral
Hepat. 10:70–79. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yin Y, Lin F, Zhuang Q, Liu L and Qian C:
Generation of full-length functional antibody against preS2 of
hepatitis B virus in hepatic cells in vitro from bicistrons
mediated by gutless adenovirus. Bio Drugs. 23:391–397.
2009.PubMed/NCBI
|
|
12
|
Salyaev RK, Stolbikov AS, Rekoslavskaya
NI, Shchelkunov SN, Pozdnyakov SG, Chepinoga AV and Hammond RV:
Obtaining tomato plants transgenic for the preS2-S-HDEL gene, which
synthesize the major hepatitis B surface antigen. Dokl Biochem
Biophys. 433:187–190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cruciani M, Mengoli C, Serpelloni G, Mazzi
R, Bosco O and Malena M: Granulocyte macrophage colony-stimulating
factor as an adjuvant for hepatitis B vaccination: a meta-analysis.
Vaccine. 25:709–718. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rizza P, Ferrantini M, Capone I and
Belardelli F: Cytokines as natural adjuvants for vaccines: where
are we now? Trends Immunol. 23:381–383. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sasaki MG, Foccacia R and de
Messias-Reason IJ: Efficacy of granulocyte-macrophage
colony-stimulating factor (GM-CSF) as a vaccine adjuvant for
hepatitis B virus in patients with HIV infection. Vaccine.
21:4545–4549. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gustavsson M, Lehtiö J, Denman S, Teeri
TT, Hult K and Martinelle M: Stable linker peptides for a
cellulose-binding domain-lipase fusion protein expressed in
Pichia pastoris. Protein Eng. 14:711–715. 2001. View Article : Google Scholar : PubMed/NCBI
|
